PAMU
AVIR icon

Pictet Asset Management (UK)’s Atea Pharmaceuticals AVIR Stock Holding History

Pictet Asset Management (UK)’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$1.55M Sell
72,193
-3,267
-4% -$98.2K ﹤0.01% 1046
2021
Q1 		$4.66M Sell
75,460
-77,044
-51% -$5.21M 0.01% 853
2020
Q4 		$6.37M Buy
+152,504
New +$4.92M 0.01% 758

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AICPI
ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

Pictet Asset Management (UK)'s AVIR Position: Q2 2021 in Review

Pictet Asset Management (UK) reduced its Atea Pharmaceuticals (AVIR) stake by 4.3% in Q2 2021, selling an estimated $98.2K and leaving 72,193 shares worth $1.55M. The position accounts for ﹤0.01% of the portfolio, ranked #1046.

Pictet Asset Management (UK) first reported a position in AVIR in Q4 2020 and has held it in 3 quarters since. The position peaked at $6.37M in Q4 2020. 103 funds tracked by Wall St. Rank hold AVIR as of Q2 2021.

  • Pictet Asset Management (UK) held 72,193 shares of Atea Pharmaceuticals worth $1.55M as of Q2 2021.
  • Pictet Asset Management (UK) sold 3,267 Atea Pharmaceuticals shares in Q2 2021, an estimated $98.2K.
  • Atea Pharmaceuticals made up ﹤0.01% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #1046 holding.
  • Pictet Asset Management (UK) first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 3 quarters since.
  • Pictet Asset Management (UK)'s Atea Pharmaceuticals position peaked at $6.37M in Q4 2020.
  • 103 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.